The Latest
-
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch in the first half of 2026
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.
-
Permission granted by Catalent
Sponsored by CatalentNavigating the complexities of Cell and Gene Therapy supply chains
Turning complex CGT logistics into certainty—keeping therapies moving to patients.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Lilly’s latest collaboration with Innovent Biologics marks the partners’ seventh alliance and Innovent’s third with a major drugmaker since the start of 2025.
Updated Feb. 9, 2026 -
Nathan Howard via Getty Images
Trump administrationWhite House’s online service for drug sales debuts with limited impact on prices
Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.
-
Getty Images
News roundupLilly bets again on China drugs; Roche showcases MS data
Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.
-
Spencer Platt via Getty Images
News roundupEarnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game
Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.
-
Getty Images
IPO windowEikon Therapeutics nets a $381M IPO amid burst of biotech offerings
Eikon’s offering ranks as the largest new biotech stock issuance since Acelyin’s $540 million haul nearly three years ago.
-
Michael M. Santiago via Getty Images
IPO windowAgomab, SpyGlass bank a combined $350M in biotech IPOs
The two offerings capped off the busiest week for new biotech stock issuances in a year.
-
Courtesy of Hims & Hers
Obesity drugsNovo, Lilly sputter as Hims launches knockoff GLP-1 pill
Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take “swift action” against those “mass-marketing illegal copycat drugs.”
Updated Feb. 6, 2026 -
Getty Images
Bayer details anticipated stroke prevention data for new blood-thinner
Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
The roughly $30 billion deal Merck had been discussing with Revolution Medicines before talks reportedly fell apart would’ve ranked as the largest drug company acquisition since Pfizer’s buyout of Seagen.
Updated Jan. 26, 2026 -
Getty Images
News roundupEarnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.
-
Permission granted by Generate Biomedicines
IPO windowGenerate, an AI-driven Flagship startup, pitches an IPO
The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.
-
Scott Olson via Getty Images
Obesity drugsLilly soars again as fast-selling weight loss drugs top Wall Street projections
Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Veradermics, Eikon Therapeutics, Agomab Therapeutics and SpyGlass Pharma collectively raised more than $1.2 billion over the course of three days, and all either met or exceeded their offering targets.
Updated Feb. 4, 2026 -
Permission granted by Novo Nordisk
Novo shares tumble by double digits on grim sales outlook
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.
-
Leigh Vogel via Getty Images
Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit
The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.
Updated Feb. 4, 2026 -
Win McNamee via Getty Images
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Sanofi’s venture arm co-led an $85 million round for QuantX Biosciences, a company that’s developing a drug aimed at an increasingly popular immunological target known as STAT6.
Updated 6 hours ago -
Getty Images
Obesity drugsPfizer dips on new data for obesity drug acquired in $10B deal
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
-
Getty Images
News roundup
FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.
-
Getty Images
Gene editingGSK walks away from pioneering Wave RNA editing drug
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.
Updated Feb. 2, 2026 -
Courtesy of Novo Nordisk
Obesity drugsNovo combination obesity shot meets goal in diabetes trial
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.
-
Courtesy of Sanofi
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.
-
Alamy
Amgen gives up on its once-prized eczema drug
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.
-
Alamy
China competitionAstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.
